Drugs / IMC008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05837299 | Apr 2023 → Dec 2025 | neoplasm | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05837299 ↗ |
| Modality | Cell therapy | “NKG2D receptor-modified autologous CAR -T cells targeting CLDN18.2” NCT05837299 ↗ |
| Target | CLDN18 | “NKG2D receptor-modified autologous CAR -T cells targeting CLDN18.2” NCT05837299 ↗ |